Hameed Ahsan, Mojsak Patrycja, Buczynska Angelika, Suleria Hafiz Ansar Rasul, Kretowski Adam, Ciborowski Michal
Clinical Research Center, Medical University of Bialystok, Jana Kilińskiego Street 1, 15-089 Bialystok, Poland.
Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-089 Bialystok, Poland.
J Clin Med. 2020 Jul 16;9(7):2257. doi: 10.3390/jcm9072257.
Diabetes mellitus, a disease of modern civilization, is considered the major mainstay of mortalities around the globe. A great number of biochemical changes have been proposed to occur at metabolic levels between perturbed glucose, amino acid, and lipid metabolism to finally diagnoe diabetes mellitus. This window period, which varies from person to person, provides us with a unique opportunity for early detection, delaying, deferral and even prevention of diabetes. The early detection of hyperglycemia and dyslipidemia is based upon the detection and identification of biomarkers originating from perturbed glucose, amino acid, and lipid metabolism. The emerging "OMICS" technologies, such as metabolomics coupled with statistical and bioinformatics tools, proved to be quite useful to study changes in physiological and biochemical processes at the metabolic level prior to an eventual diagnosis of DM. Approximately 300-400 such metabolites have been reported in the literature and are considered as predicting or risk factor-reporting metabolic biomarkers for this metabolic disorder. Most of these metabolites belong to major classes of lipids, amino acids and glucose. Therefore, this review represents a snapshot of these perturbed plasma/serum/urinary metabolic biomarkers showing a significant correlation with the future onset of diabetes and providing a foundation for novel early diagnosis and monitoring the progress of metabolic syndrome at early symptomatic stages. As most metabolites also find their origin from gut microflora, metabolism and composition of gut microflora also vary between healthy and diabetic persons, so we also summarize the early changes in the gut microbiome which can be used for the early diagnosis of diabetes.
糖尿病作为一种现代文明病,被认为是全球死亡的主要原因。人们提出,在葡萄糖、氨基酸和脂质代谢紊乱至最终诊断为糖尿病的过程中,会发生大量生化变化。这个因人而异的窗口期,为我们提供了一个早期检测、延缓甚至预防糖尿病的独特机会。高血糖和血脂异常的早期检测基于对源自葡萄糖、氨基酸和脂质代谢紊乱的生物标志物的检测和识别。新兴的“组学”技术,如代谢组学与统计和生物信息学工具相结合,已被证明在最终诊断糖尿病之前,对于研究代谢水平上生理和生化过程的变化非常有用。文献中已报道了大约300 - 400种此类代谢物,它们被认为是这种代谢紊乱的预测性或风险因素报告性代谢生物标志物。这些代谢物大多属于脂质、氨基酸和葡萄糖的主要类别。因此,本综述概述了这些与糖尿病未来发病显著相关的血浆/血清/尿液代谢生物标志物,为新的早期诊断以及在早期症状阶段监测代谢综合征的进展提供了基础。由于大多数代谢物也源自肠道微生物群,健康人和糖尿病患者的肠道微生物群的代谢和组成也有所不同,所以我们还总结了可用于糖尿病早期诊断的肠道微生物群的早期变化。